Recent years saw widening of racial and ethnic relative disparities in NO2-attributable pediatric asthma and PM2.5-attributable premature mortality
THURSDAY, March 14, 2024 (HealthDay News) — There has been a widening of racial and ethnic relative disparities in the pollution-attributable health burden within the United States, according to a study published online March 6 in Environmental Health Perspectives.
Gaige Hunter Kerr, Ph.D., from George Washington University in Washington, D.C., and colleagues quantified census tract-level variations in health outcomes attributable to nitrogen dioxide (NO2) and fine particulate matter with aerodynamic diameter ≤2.5μm (PM2.5) through a health impact assessment.
The researchers found that the public health damages associated with NO2 and PM2.5 decreased overall, but during the last decade, there was a widening of racial and ethnic relative disparities in NO2-attributable pediatric asthma and PM2.5-attributable premature mortality. Between 2010 and 2019, the racial relative disparities in PM2.5-attributable premature mortality and NO2-attributable pediatric asthma increased by 16 and 19 percent, respectively. Similarly, there were increases of 40 percent in ethnic relative disparities in PM2.5-attributable premature mortality and 10 percent in NO2-attributable pediatric asthma.
“The study also shows that the Environmental Protection Agency air quality standards are not adequately protecting Americans, especially the most marginalized communities,” Kerr said in a statement. “The adverse health effects linked to fine particulate matter and nitrogen dioxide pollution in our study occurred even though EPA air quality standards were largely met.”
Air Pollution Tied to Higher Risk for Suicide
Use of SAMA, SABA Linked to Cardiovascular Events, Mortality in Asthma, COPD
Aerobic Training, Behavioral Interventions Both Clinically Improve Asthma Control
Residential Context Has Larger Impact on Ovarian Cancer Survival in Black Women
Structured Exercise Should Be Considered as Adjunct Therapy for Cancer
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML
Cancer Risk ID"d for Asian American, NHPI Population